Advancing microbiome innovation
European Pharmaceutical Review
APRIL 10, 2024
While this approach has shown to be safe and efficient in Clostridium difficile, the variability between donors may lead to random outcomes and responses in patients for immune-mediated diseases. Notably, from one donor to another, significant variations exist. Internet] Pharmaceutical Technology.
Let's personalize your content